DXCM (DexCom) ROE % Adjusted to Book Value: 3.41% (As of Mar. 2026)


DXCM DexCom Inc DXCM
90 GF Score
Price $69.75
GF Value $103.54
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is DexCom ROE % Adjusted to Book Value?

DexCom DXCM +1.18% 90 ROE % Adjusted to Book Value is 3.41% as of Mar. 2026. GuruFocus rates DXCM with a GF Score™ of 90/100 and a GF Value™ of $103.54 (Significantly Undervalued). The stock has 3 warning signs investors should review.

DexCom's ROE % for the quarter that ended in Mar. 2026 was 27.99%. DexCom's PB Ratio for the quarter that ended in Mar. 2026 was 8.20. DexCom's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 3.41%.

DexCom ROE % Adjusted to Book Value Related Terms

DexCom ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for DexCom's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexCom ROE % Adjusted to Book Value Chart

DexCom Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.44 0.80 1.12 1.91 3.71

DexCom Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 2.23 4.45 4.20 3.41

DXCM vs GEHC, STE, ZBH: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, DexCom's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DexCom ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where DexCom's ROE % Adjusted to Book Value falls into.


DXCM
90GF Score
DexCom Inc DXCM
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexCom ROE % Adjusted to Book Value Calculation

DexCom's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=34.50% / 9.30
=3.71%

DexCom's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=27.99% / 8.20
=3.41%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 3.41% mean?
DexCom (DXCM) has a ROE % Adjusted to Book Value of 3.41% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DexCom and its competitors.
Is DexCom's ROE % Adjusted to Book Value too high?
DexCom's current ROE % Adjusted to Book Value is 3.41%. Overall, DexCom has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's ROE % Adjusted to Book Value compare to GEHC and STE?
DexCom's ROE % Adjusted to Book Value of 3.41% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DexCom and its competitors. DexCom's current ROE % Adjusted to Book Value is 3.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $103.54, compared to a current price of $69.75 — trading 32.6% below its estimated fair value. The current ROE % Adjusted to Book Value is 3.41%. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For DexCom (DXCM), the current ROE % Adjusted to Book Value is 3.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DexCom (DXCM) Overvalued in 2026?

Based on GuruFocus' analysis, DexCom stock appears to be undervalued. The current stock price of $69.75 is trading 32.6% below its estimated GF Value™ of $103.54. GuruFocus considers DexCom to be Significantly Undervalued.

Key valuation signals for DXCM:

  • ROE % Adjusted to Book Value: 3.41%
  • GF Value™: $103.54 vs. price of $69.75 (32.6% below fair value)
  • GF Score™: 90/100 with 3 warning signs

No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DexCom Business Description

Address 6340 Sequence Drive, San Diego, CA, USA, 92121
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score

Get the complete analysis for DXCM

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$69.75
Price
$103.54
GF Value